Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$42.92−0.81 (-1.85%)
Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –
Rigel Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Rigel Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $276.79M, up 3.3% year over year. For fiscal 2025 it was $294.28M, up 64.1% from the year before. The highest annual figure on record is $294.28M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $294.28M | +64.1% |
| FY2024 | Dec 31, 2024 | $179.28M | +53.4% |
| FY2023 | Dec 31, 2023 | $116.88M | -2.8% |
| FY2022 | Dec 31, 2022 | $120.24M | -19.4% |
| FY2021 | Dec 31, 2021 | $149.24M | +37.4% |
| FY2020 | Dec 31, 2020 | $108.62M | +83.2% |
| FY2019 | Dec 31, 2019 | $59.29M | +33.2% |
| FY2018 | Dec 31, 2018 | $44.51M | +892.6% |
| FY2017 | Dec 31, 2017 | $4.48M | -78.0% |
| FY2016 | Dec 31, 2016 | $20.38M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $78.70M | -22.6% |
| Q1 FY2026 | Mar 31, 2026 | $58.82M | +10.3% |
| Q4 FY2025 | Dec 31, 2025 | $69.80M | +21.2% |
| Q3 FY2025 | Sep 30, 2025 | $69.46M | +25.6% |
| Q2 FY2025 | Jun 30, 2025 | $101.69M | +176.0% |
| Q1 FY2025 | Mar 31, 2025 | $53.33M | +80.6% |
| Q4 FY2024 | Dec 31, 2024 | $57.60M | +60.9% |
| Q3 FY2024 | Sep 30, 2024 | $55.31M | +96.6% |
| Q2 FY2024 | Jun 30, 2024 | $36.84M | +37.0% |
| Q1 FY2024 | Mar 31, 2024 | $29.53M | +13.3% |
| Q4 FY2023 | Dec 31, 2023 | $35.79M | -30.2% |
| Q3 FY2023 | Sep 30, 2023 | $28.13M | +25.5% |
| Q2 FY2023 | Jun 30, 2023 | $26.89M | -9.8% |
| Q1 FY2023 | Mar 31, 2023 | $26.07M | +55.8% |
| Q4 FY2022 | Dec 31, 2022 | $51.28M | +151.3% |
| Q3 FY2022 | Sep 30, 2022 | $22.41M | +4.0% |
| Q2 FY2022 | Jun 30, 2022 | $29.82M | +13.5% |
| Q1 FY2022 | Mar 31, 2022 | $16.74M | -79.3% |
| Q4 FY2021 | Dec 31, 2021 | $20.41M | +10.6% |
| Q3 FY2021 | Sep 30, 2021 | $21.54M | +17.2% |
| Q2 FY2021 | Jun 30, 2021 | $26.27M | +63.9% |
| Q1 FY2021 | Mar 31, 2021 | $81.02M | +45.3% |
| Q4 FY2020 | Dec 31, 2020 | $18.45M | +19.8% |
| Q3 FY2020 | Sep 30, 2020 | $18.39M | -11.8% |
| Q2 FY2020 | Jun 30, 2020 | $16.02M | +53.9% |
| Q1 FY2020 | Mar 31, 2020 | $55.76M | +341.7% |
| Q4 FY2019 | Dec 31, 2019 | $15.40M | -59.3% |
| Q3 FY2019 | Sep 30, 2019 | $20.86M | +328.7% |
| Q2 FY2019 | Jun 30, 2019 | $10.41M | +482.4% |
| Q1 FY2019 | Mar 31, 2019 | $12.62M | – |
| Q4 FY2018 | Dec 31, 2018 | $37.86M | +4106.3% |
| Q3 FY2018 | Sep 30, 2018 | $4.87M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.79M | -50.1% |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $900.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $3.58M | – |
See a number that looks wrong?